Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study - Report - MDSpire
Advertisement
Incremental prognostic value of the fibrinogen−to−albumin ratio for adverse perinatal outcomes in preeclampsia: a dual−center retrospective cohort study
Clinical Report: Enhanced Prognostic Significance of the Fibrinogen-to-Albumin Ratio
Overview
The fibrinogen-to-albumin ratio (FAR) significantly improves the prediction of adverse perinatal outcomes in preeclamptic patients. This study demonstrates that incorporating FAR into existing models enhances risk stratification and informs clinical decision-making.
Background
Preeclampsia is a serious condition affecting 5%-7% of pregnancies and is a leading cause of maternal and perinatal morbidity and mortality. Accurate risk assessment is crucial for managing preeclampsia, as it can lead to severe complications such as placental abruption and eclampsia. The identification of reliable biomarkers like FAR can aid in the timely intervention and management of these patients.
Data Highlights
Model
AUC
ΔAUC
NRI
IDI
Model A
0.852
-
-
-
Model B
0.888
0.010
0.397
0.022
Key Findings
Model B (including FAR) showed improved AUC of 0.888 compared to Model A's 0.852.
FAR ≥0.135 achieved a sensitivity of 0.864 and specificity of 0.740 for predicting composite adverse perinatal outcomes (CAPO).
In external validation, Model B maintained an AUC of 0.856, outperforming Model A (AUC 0.798).
The addition of FAR resulted in a continuous NRI of 0.397, indicating significant improvement in risk reclassification.
Subgroup analyses confirmed the robustness of the findings across different patient demographics.
Clinical Implications
The incorporation of FAR into clinical practice can enhance the ability to identify preeclamptic patients at high risk for severe perinatal outcomes. This information can guide anesthesiologists in making informed decisions regarding perioperative care and monitoring.
Conclusion
FAR serves as a valuable prognostic tool in preeclampsia, providing significant incremental value in predicting adverse outcomes. Its integration into clinical protocols may improve patient management and outcomes.
